Research on CD47 is rapidly evolving. Several biotech companies are developing anti-CD47 antibodies and other therapeutic agents. Clinical trials are underway to assess the safety and efficacy of these therapies in patients with various types of cancer. Additionally, researchers are exploring combination therapies that target CD47 along with other immune checkpoints to maximize therapeutic benefits.
